Overview: TORCH Antigen + IgG/IgM Antibody Rapid TestIntroduction: The TORCH Antigen + IgG/IgM Antibody Rapid Test is a diagnostic tool designed to detect TORCH antigens and IgG/IgM antibodies in serum, whole blood, or saliva samples, facilitating the screening of TORCH infections, an acronym for Toxoplasma gondii, Rubella virus, Cytomegalovirus (CMV), and Herpes Simplex Virus (HSV). These congenital infections pose significant risks during pregnancy, presenting with fever, rash, and severe complications like congenital anomalies (e.g., microcephaly, deafness, or mental retardation) if transmitted to the fetus, particularly in primary maternal infections. Per the 2023 American College of Obstetricians and Gynecologists guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for early detection in prenatal care. This rapid diagnostic falls under virology and targets pregnant women, immunocompromised individuals, or those with unexplained symptoms, addressing the challenge of identifying asymptomatic or early infections to prevent fetal harm. With morbidity rates elevated due to congenital effects, the test supports preventive measures such as vaccination (for rubella), antiviral therapy (for CMV or HSV), and hygiene education. It aids public health by enabling timely intervention and reducing the incidence of congenital TORCH syndromes.Other Names: TORCH Combo Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by InBios, this test marked a significant advancement in multiplex screening for congenital infections, enhancing prenatal diagnostics.Purpose: The test screens for TORCH antigens and IgG/IgM to guide infection staging, assess maternal immunity, and inform treatment and prevention strategies during pregnancy.Test Parameters: Presence of TORCH Antigen and IgG/IgM Antibody, detected with high specificity to indicate acute or past infection, with IgM suggesting recent exposure and IgG indicating past immunity or chronic infection.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, rash, pregnancy, or exposure to TORCH pathogens.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen and antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature sensitive components, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fever, rash, pregnancy history, or exposure to cats (Toxoplasma), unvaccinated contacts (Rubella), or genital sores (HSV), as well as any prior TORCH-related illnesses.Consent: Written informed consent is required, detailing the test's purpose, potential risks of congenital infection including fetal anomalies, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-reactivity with other viral infections, or early infection before antibody development can affect results. Correlation with PCR, IgG avidity testing, or clinical evaluation is recommended to confirm findings and distinguish acute from past infection.Clinical Significance: A positive IgM result indicates acute TORCH infection, necessitating immediate intervention (e.g., antivirals for CMV, termination consideration for severe cases), while a positive IgG suggests past immunity or chronic infection, requiring monitoring. A negative result may require follow-up testing if symptoms persist or if sampled too early in pregnancy.Specialist Consultation: Obstetricians, infectious disease specialists, or maternal-fetal medicine experts should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: TORCH-specific PCR, IgG avidity for timing, or amniotic fluid analysis for fetal confirmation.Test Limitations: The test may produce false positives due to cross-reactivity with other viruses or false negatives in early infection or immunocompromised patients, requiring a comprehensive diagnostic approach that includes serology, molecular methods, and ultrasound for definitive diagnosis.References: ACOG Guidelines 2023, Journal of Clinical Virology 2024, Pediatrics 2025.